Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study

Bipolar Disease Type I Clinical Trial

— CHAPS  

Official title:

Biomarkers for Bipolar Disorder: Chaperones and Reticulum Endoplasmatic Stress Response CHAP´s Study

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT00994630
• Other study ID #: CHAPS STUDY
• Status: Suspended
• Phase: N/A
• First received: October 13, 2009
• Last updated: August 15, 2011
• Start date: January 2010

Study information

• Verified date: May 2011
• Source: University of Sao Paulo
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: National Committee of Ethics in Research
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine expression of chaperones proteins from the endoplasmatic reticulum stress response system in bipolar I patients (manic phase) compared to healthy controls.

Hypothesis: There is no difference in chaperones proteins expression between bipolar I manic patients and healthy controls

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 20
• Est. primary completion date: August 2011
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Bipolar Disease type I manic phase

• YMRS > 14

• HDRS < 9

Exclusion Criteria:

• Use of lithium, divalproate, or carbamazepine in therapeutic levels over the past 30 days

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Bipolar Disease Type I
• Bipolar Disorder

Locations

Country	Name	City	State
Brazil	Mood Disorders Program, Institute of Psychiatry, Faculty of Medicine, University of Sao Paulo	Sao paulo

Sponsors (1)

Lead Sponsor	Collaborator
University of Sao Paulo

Country where clinical trial is conducted

Brazil,